Analysis of a targeted receptor tyrosine kinase inhibitor in the treatment of acute myelogenous leukemia.

被引：0
|
作者：
Menzel, LP
Shankar, DB
Shah, NP
Hummerickhouse, R
Hagey, A
Sakamoto, KM
Moore, TB
机构：
[1] Univ Calif Los Angeles, Dept Pediat, David Geffen Sch Med, Los Angeles, CA 90024 USA
[2] Univ Calif Los Angeles, Dept Med, David Geffen Sch Med, Los Angeles, CA 90024 USA
[3] Abbott Labs Inc, Chicago, IL USA
[4] CALTECH, Pasadena, CA 91125 USA
来源：
JOURNAL OF INVESTIGATIVE MEDICINE | 2005年 / 53卷 / 01期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
156
引用
收藏
页码：S105 / S105
页数：1
相关论文
共 50 条
  • [1] Clinical efficacy and safety of an ABL specific tyrosine kinase inhibitor as targeted therapy for chronic myelogenous leukemia.
    Druker, BJ
    Talpaz, M
    Resta, D
    Peng, B
    Buchdunger, E
    Ford, J
    Sawyers, CL
    BLOOD, 1999, 94 (10) : 368A - 368A
  • [2] VX-322: A Novel Dual Receptor Tyrosine Kinase Inhibitor for the Treatment of Acute Myelogenous Leukemia
    Heidary, David K.
    Huang, George
    Boucher, Diane
    Ma, Jianguo
    Forster, Cornelia
    Grey, Ron
    Xu, Jinwang
    Arnost, Michael
    Choquette, Deborah
    Chen, Guanjing
    Zhou, Jie-Hua
    Yao, Yung-Mae
    Ball, Edward D.
    Namchuk, Mark
    Davies, Robert J.
    Henkel, Greg
    JOURNAL OF MEDICINAL CHEMISTRY, 2012, 55 (02) : 725 - 734
  • [3] Discovery of CT53518, a potent and oral inhibitor of FLT3 kinase targeted for the treatment of acute myelogenous leukemia.
    Pandey, A
    Volkots, DL
    Seroogy, J
    Rose, J
    Yu, JC
    Hutchaleelaha, A
    Giese, N
    Scarborough, RM
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2002, 223 : A90 - A90
  • [4] Structural mechanism for the inhibition of Abelson tyrosine kinase by a small molecule inhibitor that is effective in the treatment of chronic myelogenous leukemia.
    Schindler, T
    Vidal, E
    Bornmann, WG
    Pellicena, P
    Miller, WT
    Clarkson, B
    Kuriyan, J
    CLINICAL CANCER RESEARCH, 2000, 6 : 4544S - 4544S
  • [5] Nilotinib: A New Tyrosine Kinase Inhibitor for the Treatment of Chronic Myelogenous Leukemia
    Jarkowski, Anthony, III
    Sweeney, Richard P.
    PHARMACOTHERAPY, 2008, 28 (11): : 1374 - 1382
  • [6] SU5416, a receptor tyrosine kinase inhibitor, is active in preclinical models of acute myeloid leukemia.
    Bertolini, F
    Dell'Agnola, C
    Gobbi, A
    Monestiroli, S
    Pruneri, G
    McMahon, G
    Martinelli, G
    BLOOD, 2000, 96 (11) : 117A - 117A
  • [7] Tyrosine Kinase Targeted Treatment of Chronic Myelogenous Leukemia and Other Myeloproliferative Neoplasms
    Bisen, Ajit
    Claxton, David F.
    IMPACT OF GENETIC TARGETS ON CANCER THERAPY, 2013, 779 : 179 - 196
  • [8] Dasatinib: A tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia
    Steinberg, Michael
    CLINICAL THERAPEUTICS, 2007, 29 (11) : 2289 - 2308
  • [9] The tyrosine kinase inhibitor STI571 prolongs survival in a murine model of chronic myelogenous leukemia.
    Wolff, NC
    Xu, HM
    Zhang, SM
    Ilaria, RL
    BLOOD, 2000, 96 (11) : 344A - 344A
  • [10] STI571, a tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia: validating the promise of molecularly targeted therapy
    Michael J. Mauro
    Michael E. O'Dwyer
    Brian J. Druker
    Cancer Chemotherapy and Pharmacology, 2001, 48 : S77 - S78
12345